Chromatography

Global WholeHealth Partners Corp.'s (OTC: GWHP) Antibody IgG/IgM and Antigen Tests That They Offer Are Capable of Detecting the DELTA B.1.617.2, United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) of COVID 19 SARS 2

Monday, July 26, 2021 - 12:00pm

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • The government is working with the diagnostics industry to ensure the gains in domestic manufacturing are not lost over time.
  • To conquer COVID and win this war, Global must keep up the research and development of tests.
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.

Chromatography Software Market Size To Reach $1.8 Billion By 2028: Grand View Research, Inc.

Monday, July 26, 2021 - 9:05am

SAN FRANCISCO, July 26, 2021 /PRNewswire/ -- The global chromatography software market size is expected to reach USD 1.8 billion by 2028, based on a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 26, 2021 /PRNewswire/ -- The global chromatography software market size is expected to reach USD 1.8 billion by 2028, based on a new report by Grand View Research, Inc.
  • The market is expected to expand at a CAGR of 8.9% from 2021 to 2028.
  • The usage of chromatography technology in research activities and growing automation and technological integration for improved efficiency and performance are further boosting the market growth.
  • Grand View Research has segmented the global chromatography software market based on type, deployment model, application, and region:
    Chromatography Software Type Outlook (Revenue, USD Million, 2016 - 2028)
    Chromatography Software Deployment Model Outlook (Revenue, USD Million, 2016 - 2028)
    Chromatography Software Application Outlook (Revenue, USD Million, 2016 - 2028)

Chromatography Software Market Size To Reach $1.8 Billion By 2028: Grand View Research, Inc.

Monday, July 26, 2021 - 9:05am

SAN FRANCISCO, July 26, 2021 /PRNewswire/ -- The global chromatography software market size is expected to reach USD 1.8 billion by 2028, based on a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 26, 2021 /PRNewswire/ -- The global chromatography software market size is expected to reach USD 1.8 billion by 2028, based on a new report by Grand View Research, Inc.
  • The market is expected to expand at a CAGR of 8.9% from 2021 to 2028.
  • The usage of chromatography technology in research activities and growing automation and technological integration for improved efficiency and performance are further boosting the market growth.
  • Grand View Research has segmented the global chromatography software market based on type, deployment model, application, and region:
    Chromatography Software Type Outlook (Revenue, USD Million, 2016 - 2028)
    Chromatography Software Deployment Model Outlook (Revenue, USD Million, 2016 - 2028)
    Chromatography Software Application Outlook (Revenue, USD Million, 2016 - 2028)

Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums

Thursday, July 22, 2021 - 5:45pm

For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.

Key Points: 
  • For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.
  • Now the FDA has released guidance to BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) for its T-cell immune response diagnostic platform CoviDTH to begin Phase I/II Clinicial Trials.
  • However, later in July, Abbott was reported to be working to import the PanBio Covid-19 self tests from Korea.
  • The Sofia test was the first rapid antigen test to get an FDA greenlight , back in May of last year.

Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums

Thursday, July 22, 2021 - 5:45pm

VANCOUVER, B.C., July 22, 2021 /PRNewswire/ -- USA News Group  -  Two of the world's most prominent billionaires, George Soros and Bill Gates, recently made headlines backing a consortium to buy UK Covid-19 test maker Mologic for $41 million ahead of a new initiative of a global rollout for rapid result testing. As demand shifts, newer innovations from not only from Mologic are gaining attention, including a new T-Cell Immune Response diagnostic from BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV), antigen tests from Abbott Laboratories (NYSE: ABT), Chembio Diagnostics, Inc. (NASDAQ: CEMI) and Quidel Corporation (NASDAQ: QDEL), and antibody tests from Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX).

Key Points: 
  • For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.
  • Now the FDA has released guidance to BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) for its T-cell immune response diagnostic platform CoviDTH to begin Phase I/II Clinicial Trials.
  • However, later in July, Abbott was reported to be working to import the PanBio Covid-19 self tests from Korea.
  • The Sofia test was the first rapid antigen test to get an FDA greenlight , back in May of last year.

Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil

Wednesday, July 21, 2021 - 3:56am

HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio’s DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil’s Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab. Chembio’s delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembio’s supply chain, staffing, and liquidity, and other matters outside Chembio’s control.

Key Points: 
  • The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab.
  • Chembio has a long-standing relationship with Bio-Manguinhos, having supplied multiple products for point-of-care detection of COVID-19 antibodies, HIV, and other infectious diseases.
  • We believe the purchase order validates the investments we made earlier this year in inventory for the DPP SARS-CoV-2 Antigen test and look forward to ramping up production.
  • Chembios portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA).

State of Delaware Selects Quidel for COVID-19 Testing Program at Schools

Monday, July 19, 2021 - 3:30pm

Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.
  • Students and faculty that opt-in to the COVID-19 screening program will be tested with Quidels rapid antigen tests.
  • DPH and Delawares Department of Education will launch the initiative at five pilot schools for summer school enrollees.
  • Quidel can expand the program to all of the States K-12 schools when classrooms fully reopen for the fall semester.

Trinity Biotech Provides A Business Development Update For Q2 2021

Friday, July 16, 2021 - 1:00pm

DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.

Key Points: 
  • DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.
  • Trinity Biotech has been the main confirmatory test provider for the detection of the HIV virus on the African continent over many years.
  • In June 2021, the Company received an update from the WHO on the approval process.
  • Trinity Biotech is at an advanced stage in the development of a SARS-CoV-2 antigen test.

Ninonasal® Antigen Self-Tests Made in France

Friday, July 16, 2021 - 11:54am

NG Biotech presents Ninonasal, the COVID-19 antigen self-test thats detecting Delta and Epsilon variants.

Key Points: 
  • NG Biotech presents Ninonasal, the COVID-19 antigen self-test thats detecting Delta and Epsilon variants.
  • View the full release here: https://www.businesswire.com/news/home/20210716005156/en/
    NG Biotech presents Ninonasal, the COVID-19 antigen self-test thats detecting Delta and Epsilon variants.
  • In France, Ninonasal is assembled into kits and distributed by Boiron Laboratories in order to strengthen its fully made in France character.
  • With Ninonasal, we did not just launch another rapid antigen test.

Capillary Electrophoresis Market|COVID-19 Impact Analysis|Technavio

Tuesday, July 13, 2021 - 11:30pm

The capillary electrophoresis market is poised to grow by USD 248.09 million during 2021-2025, progressing at a CAGR of 5.85% during the forecast period.

Key Points: 
  • The capillary electrophoresis market is poised to grow by USD 248.09 million during 2021-2025, progressing at a CAGR of 5.85% during the forecast period.
  • The report on the capillary electrophoresis market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The capillary electrophoresis market analysis includes end-user and geography landscape segments.
  • This study identifies the rising prevalence of chronic conditions as one of the prime reasons driving the capillary electrophoresis market growth during the next few years.